Search Within

Kathryn Cecilia Arbour

Formats
  1. Meeting Abstract (43)
  2. Journal Article (42)
  3. Editorial (2)
  4. Review (2)
Groups
  1. Department of Medicine (89)
  2. Solid Tumor Oncology Division (89)
  3. Thoracic Oncology (89)
  4. Weinberg Fellows (89)
  5. GSK Faculty (39)
  6. Radiology, Department of (34)

More Groups

People
  1. Gregory Riely (42)
  2. Matthew Hellmann (40)
  3. Hira Rizvi (32)
  4. Andrew Plodkowski (23)
  5. Charles Rudin (22)
  6. Mark Kris (22)

More People

Years
  1. 2025 (5)
  2. 2024 (10)
  3. 2023 (8)
  4. 2022 (9)
  5. 2021 (11)
  6. 2020 (9)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Annals of Oncology (11)
  3. Journal of Thoracic Oncology (11)
  4. Clinical Cancer Research (6)
  5. Cancer Research (4)
  6. Cancer Discovery (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (32)
  2. Elsevier Inc. (16)
  3. American Association for Cancer Research (13)
  4. Oxford University Press (13)
  5. Nature Publishing Group (4)
  6. Massachusetts Medical Society (2)

More Publishers

Results (89)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ml-RECIST: Machine learning to estimate RECIST in patients with NSCLC treated with PD-(L)1 blockade
    Meeting Abstract

    Arbour, K. C.; Tuan, L. A.; Rizvi, H.; Yala, A.; Hellmann, M. D.; Barzilay, R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%
    Meeting Abstract

    Jimenez Aguilar, E.; Ricciuti, B.; Gainor, J. F.; Nishino, M.; Adeni, A. E.; Subegdjo, S.; Khosrowjerdi, S.; Peterson, R.; Digumarthy, S.; Liu, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
    Journal Article

    Schoenfeld, A. J.; Arbour, K. C.; Rizvi, H.; Iqbal, A. N.; Gadgeel, S. M.; Girshman, J.; Kris, M. G.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review
    Review

    Arbour, K. C.; Riely, G. J.
    JAMA - Journal of the American Medical Association (2019)

    Fulltext@MSK | Save
  • Harnessing clinical sequencing data for survival stratification of patients with metastatic lung adenocarcinomas
    Journal Article

    Shen, R.; Martin, A.; Ni, A.; Hellmann, M.; Arbour, K. C.; Jordan, E.; Arora, A.; Ptashkin, R.; Zehir, A.; Kris, M. G.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Exceptional responders with invasive mucinous adenocarcinomas: A phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
    Journal Article

    Drilon, A.; Schoenfeld, A. J.; Arbour, K. C.; Litvak, A.; Ni, A.; Montecalvo, J.; Yu, H. A.; Panora, E.; Ahn, L.; Kennedy, M.; more...
    Cold Spring Harbor Molecular Case Studies (2019)

    Fulltext@MSK | Save
  • EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: Clinical outcomes
    Review

    Marcoux, N.; Gettinger, S. N.; O'Kane, G.; Arbour, K. C.; Neal, J. W.; Husain, H.; Evans, T. L.; Brahmer, J. R.; Muzikansky, A.; Bonomi, P. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Prognostic relevance of tumor sequencing in metastatic lung adenocarcinomas
    Meeting Abstract

    Shen, R.; Martin, A.; Ni, A.; Hellmann, M. D.; Jordan, E.; Arora, A.; Ptashkin, R.; Zehir, A.; Kris, M. G.; Arbour, K. C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • RET-rearranged lung cancers: Immunophenotype and response to immunotherapy
    Meeting Abstract

    Sabari, J. K.; Offin, M. D.; Wu, S. L.; Ni, A.; Halpenny, D.; Montecalvo, J.; Liu, D.; Pak, T. K.; Arbour, K. C.; Lai, W. C. V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and molecular features predicting long-term response (LTR) to anti-PD-(L)1 based therapy in patients with NSCLC
    Meeting Abstract

    Rizvi, H.; Plodkowski, A. J.; Tenet, M.; Halpenny, D.; Long, N.; Sauter, J. L.; Sanchez-Vega, F.; Chatila, W. K.; Schultz, N.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save